LC/MS

Bruker Introduces Novel 4D-Proteomics™ timsTOF® Capabilities

Retrieved on: 
Monday, September 18, 2023
Research, Technology, Medical Supplies, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, Science, Informatics, LC, BRKR, MALDI, Urine, Serum, TIMS, SP3, Pathology, University of Mainz, Proteomics, Demichev, Multimedia, PG, Biomarker, DDA, Assistant, Associate, Harvard Medical School, Plasma, De novo peptide sequencing, Protein, Acquisition, Kyoto University, Saliva, LC-MS, Ultra, CCS, CSF, MS/MS, Hospital, Fluid mechanics, LC/MS, Boston Children's Hospital, Peptide, Fine chemical, Bruker

View the full release here: https://www.businesswire.com/news/home/20230918138030/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230918138030/en/
    Bruker introduces TIMSquant a scalable, CCS-enabled AI-powered label-free quantification algorithm integrated into Bruker ProteoScape™.
  • We leverage the robustness of our timsTOF instruments and real-time Bruker ProteoScape to build large spectral libraries and analyze 1000s of clinical research samples.
  • Bruker is initiating a limited early-access program for midia-PASEF for immunopeptidomics and post-translational modifications (PTMs) on the ultra-sensitive timsTOF Ultra.
  • To all colleagues in search of top-tier high-throughput data, I endorse the PepSep MAX HT.”
    To ensure optimal run conditions for every sample, Bruker introduces TwinScape™, a digital twin for the timsTOF platform, using Bruker ProteoScape software and the Biognosys iRT kit.

Allotrope Foundation Releases a Vendor Agnostic and an Industry Interoperable Data Model for Laboratory Walk-up Liquid Chromatography/Mass Spectrometry Instrumentation

Retrieved on: 
Friday, September 8, 2023
JSON, Allotrope Foundation, Food, ASMS, Internet, Mass spectrometry, Liquid chromatography–mass spectrometry, Chromatography, ASM, Intelligence, Research, Organization, JavaScript, Acquisition, Simple Model of the Atmospheric Radiative Transfer of Sunshine, Collection, Laboratory, Mass, Drug discovery, LC/MS, Walkdown, FAIR, APN, Software, Instrumentation, Management, Phosphorus, Allotropy

WASHINGTON, Sept. 7, 2023 /PRNewswire-PRWeb/ -- Allotrope Foundation, an international consortium of chemical & life sciences organizations, is excited to release a vendor agnostic and an industry interoperable data model for laboratory Walk-up Liquid Chromatography/Mass Spectrometry (LC/MS) instrumentation. The technique provides users a method of submitting samples to LC/MS instruments for automated data acquisition and analysis without the need for prior scheduling. Since it allows researchers to quickly and easily obtain data, it is commonly employed in research laboratories, industrial settings, and academic institutions for a wide range of applications including during drug discovery and development, food and beverage analysis, as well as environmental samples analysis. LC/MS combines the separation capabilities of liquid chromatography with the sensitive detection and identification capabilities of mass spectrometry. Via Walk-up LC/MS a researcher can rapidly obtain information about a sample's composition, structure, and quantity.

Key Points: 
  • WASHINGTON, Sept. 7, 2023 /PRNewswire-PRWeb/ -- Allotrope Foundation, an international consortium of chemical & life sciences organizations, is excited to release a vendor agnostic and an industry interoperable data model for laboratory Walk-up Liquid Chromatography/Mass Spectrometry (LC/MS) instrumentation.
  • LC/MS combines the separation capabilities of liquid chromatography with the sensitive detection and identification capabilities of mass spectrometry.
  • The Walkup LC/MS data model was developed by the Allotrope Foundation's Mass Spectrometry Working Group, comprised of subject matter experts from Allotrope Foundation and Allotrope Partner Network (APN) member organizations.
  • Working together, these interoperable data models promote collaboration, efficiency, and data quality in research and accelerate advancement in drug discovery.

Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023

Retrieved on: 
Friday, June 2, 2023
Technology, Biotechnology, Chemicals, Plastics, Health, Manufacturing, Other Science, Other Technology, Research, Medical Devices, Software, Hardware, Science, Other Manufacturing, Electronic Design Automation, ECD, Life, ASMS, Mass spectrometry, Deep learning, George R. Brown Convention Center, Intelligence, Automation, Marriott Marquis, Agilent Technologies, LC/MS, News, NYSE, Conference, HPLC, Management, Fine chemical

Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics , being held June 4 - 8 in Houston, Texas.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics , being held June 4 - 8 in Houston, Texas.
  • Agilent is a global leader in the mass spectrometry market, providing advanced, intelligent instruments featuring improved analytical performance solutions for analytical labs worldwide.
  • “Agilent is leading the way in the trend towards developing more self-aware and intelligent instruments,” said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions.
  • The new Agilent 1260 Infinity II Hybrid Multisampler will be on show, an HPLC autosampler that offers classical Flow-through and Agilent Feed Injection modes.

Life Science Instrumentation Market worth $73.9 billion | MarketsandMarkets

Retrieved on: 
Friday, May 12, 2023
Allergy, Antigen, Food, GC/MS, Immunogenetics, Health, Genetics, HLA, Transfusion medicine, Allele, NGS, Shimadzu, Personalized medicine, AB, Thermo Fisher Scientific, Element, Danaher Corporation, Science, Patient, Risk, Organ transplantation, Algorithm, Immune system, Cancer, Medicine, Agilent Technologies, Diagnosis, Waters Corporation, Research, LC/MS, Mindful Scientific Inc., Safety, Dentistry, Vaccine, Medical imaging

Life Science Instrumentation Market Advantages:

Key Points: 
  • Life Science Instrumentation Market Advantages:
    Improved Organ Transplantation Success: Accurate Life Science Instrumentation plays a critical role in organ transplantation.
  • Rapid Technological Advancements: The Life Science Instrumentation market benefits from ongoing technological advancements, such as next-generation sequencing (NGS), high-resolution molecular techniques, and advanced data analysis algorithms.
  • Overall, the Life Science Instrumentation market offers significant advantages, including improved organ transplantation outcomes, personalized medicine approaches, enhanced disease diagnosis and treatment, advancements in transfusion medicine, scientific research opportunities, and rapid technological progress.
  • These advantages contribute to the growing importance and widespread utilization of Life Science Instrumentation in the field of healthcare.

Life Science Instrumentation Market worth $73.9 billion | MarketsandMarkets

Retrieved on: 
Friday, May 12, 2023
Allergy, Antigen, Food, GC/MS, Immunogenetics, Health, Genetics, HLA, Transfusion medicine, Allele, NGS, Shimadzu, Personalized medicine, AB, Thermo Fisher Scientific, Element, Danaher Corporation, Science, Patient, Risk, Organ transplantation, Algorithm, Immune system, Cancer, Medicine, Agilent Technologies, Diagnosis, Waters Corporation, Research, LC/MS, Mindful Scientific Inc., Safety, Dentistry, Vaccine, Medical imaging

Life Science Instrumentation Market Advantages:

Key Points: 
  • Life Science Instrumentation Market Advantages:
    Improved Organ Transplantation Success: Accurate Life Science Instrumentation plays a critical role in organ transplantation.
  • Rapid Technological Advancements: The Life Science Instrumentation market benefits from ongoing technological advancements, such as next-generation sequencing (NGS), high-resolution molecular techniques, and advanced data analysis algorithms.
  • Overall, the Life Science Instrumentation market offers significant advantages, including improved organ transplantation outcomes, personalized medicine approaches, enhanced disease diagnosis and treatment, advancements in transfusion medicine, scientific research opportunities, and rapid technological progress.
  • These advantages contribute to the growing importance and widespread utilization of Life Science Instrumentation in the field of healthcare.

Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models

Retrieved on: 
Tuesday, April 18, 2023
Orange County Convention Center, DOX, AACR, Liver disease, Hepatocellular carcinoma, ANN, Schweizer SGU 1-6, MIA, Survival, Pharmacokinetics, American Association for Cancer Research, Research, Experiment, Hyperrectangle, MD Anderson Cancer Center, Plasma, Death, Animal, American Society for Pharmacology and Experimental Therapeutics, Division, University, Proteasome inhibitor, Doxorubicin, Topoisomerase, Mouse, Liver, HEPA, Anthracycline, Therapy, LC/MS, Virus, HCC, Medical imaging, Pharmaceutical industry

HOUSTON, April 18, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that positive preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. This research was sponsored by the Company.

Key Points: 
  • "Annamycin has continued to demonstrate in preclinical models promising results in hard-to-treat tumors.
  • The high antitumor activity seen preclinically with Annamycin is very encouraging and provides validation for expanded studies to assess activity in different tumor liver metastasis models as well as HCC models," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin .
  • The antitumor efficacy of L-ANN was studied using HEPA 1-6 hepatocellular carcinoma models (subcutaneous, orthotopic, and experimental liver metastatic models) as well as CT26 colon cancer and MIA PaCa-2 pancreatic cancer liver metastasis models.
  • Unless specifically noted otherwise, references to "Annamycin" refer to the liposome formulated form of the drug.

Agilent Announced as Instrument Business Outlook 2022 Company of the Year

Retrieved on: 
Monday, March 20, 2023
Technology, Recycling, Professional Services, Environmental, Social and Governance (ESG), Environment, Telecommunications, Sustainability, Software, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, ECD, Partnership, GC/MS, Seahorse, Bioinformatics, PSS, Research, Acquisition, Investment, Artificial intelligence, Growth, IBO, Virtual Control, ESG, Helium, Spiral Dynamics, LC/MS, NYSE, Renewable energy, Fine chemical, Agilent Technologies

Agilent Technologies Inc. (NYSE: A) announced today that it has been selected as Instrument Business Outlook (IBO) 2022 Company of the Year.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) announced today that it has been selected as Instrument Business Outlook (IBO) 2022 Company of the Year.
  • Innovations noted included the HydroInert source, which allows for using of hydrogen instead of helium as the carrier gas in GC/MS.
  • Also, the introductions of new versions of the AssayMAP Bravo Protein Sample Prep Workbench and the Seahorse XF Pro Analyzer.
  • Tanya Samazan, managing editor at IBO noted: “Agilent’s achievements were about annual results as well as years of transforming the company.

The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, February 27, 2023
LC/MS, HILIC, IND, Doctor of Philosophy, Therapy, LAL, Drug discovery, HIC, MALS, Pharmaceutical industry, Vaccine

TORONTO, Feb. 27, 2023 /PRNewswire-PRWeb/ -- Bioanalytical testing is a critical component to all successful drug discovery and development programs. IND-enabling studies require that biotherapeutic proteins or biologics undergo rigorous testing to increase the likelihood of being developed into drug products. Using a set of biochemical and biophysical assays, the purity, structural integrity and chemical stability of potential biotherapeutics are established and used to determine the candidates with favorable profiles to advance or redesign. In this webinar, the featured speaker will explore the role of protein analytics in the advancement of biotherapeutic drug discovery and development.

Key Points: 
  • TORONTO, Feb. 27, 2023 /PRNewswire-PRWeb/ -- Bioanalytical testing is a critical component to all successful drug discovery and development programs.
  • IND-enabling studies require that biotherapeutic proteins or biologics undergo rigorous testing to increase the likelihood of being developed into drug products.
  • In this webinar, the featured speaker will explore the role of protein analytics in the advancement of biotherapeutic drug discovery and development.
  • Join Frank Herkules, PhD, Scientist – Protein Analytics, Aragen Biosciences , for the live webinar on Thursday, March 16, 2023, at 11am EDT (4pm CET/EU-Central).

Biosero and Virscidian Announce Collaboration for Medicinal Chemistry Applications in Drug Discovery

Retrieved on: 
Tuesday, January 31, 2023
Science, Software, Other Science, Biotechnology, Pharmaceutical, Health, Data Management, Technology, Mass spectrometry, Drug discovery, Intelligence, Pharmacokinetics, LC/MS, DMPK, Pharmaceutical industry, Fine chemical

Virscidian developed the Analytical Studio platform (including Analytical Studio Professional™ and Analytical Studio Express™ software) to accelerate drug discovery.

Key Points: 
  • Virscidian developed the Analytical Studio platform (including Analytical Studio Professional™ and Analytical Studio Express™ software) to accelerate drug discovery.
  • By working together, Biosero and Virscidian are enabling their customers to easily transfer data between these software platforms so that full medicinal chemistry and analytical workflows can be automated.
  • Biosero and Virscidian are currently working together on more than 10 projects around the world where customers are already realizing the benefits of this collaboration.
  • We are pleased to join forces with Virscidian as we make this connection between our software platforms to help customers streamline drug discovery from synthesis through to registered material and screening results.”

Novel Spectrometry Platforms Market, 2022-2035: Need for Automation, Reproducibility and Higher Sensitivity Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Technology, Other Technology, USD, Miniaturization, Novel, Benchmarking, Mass spectrometry, Biotechnology, Patent, Partnership, Element, CPC, Harvey, GC/MS, SWOT, Quality control, Automation, Food, LC/MS, NMR, XRF, Development director, Type, LECO, Video game, Uranium, 3D printing, Mobile phone, Marketing

The growing popularity of novel spectrometry platforms is also evident from 60+ global events that have been organized in this field, since 2016.

Key Points: 
  • The growing popularity of novel spectrometry platforms is also evident from 60+ global events that have been organized in this field, since 2016.
  • Elaborate profiles of the players offering novel spectrometry platforms (shortlisted on the basis of the year of experience of the company).
  • An analysis of various developments / recent trends related to novel spectrometry, offering insights on partnerships and collaborations and recent initiatives being undertaken related to novel spectrometry platforms.
  • What is the focus area of the ongoing research activities related to novel spectrometry platforms?